A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers

Li, Zhen; Ji, Kun; Bai, Liangliang; Wang, Caihong; Hu, Yingying; Shi, Yang; Zhan, Pengchao; Song, Lijie; Li, Xin; Duan, Xuhua; Han, Xinwei

doi:10.1097/md.0000000000020878

Cited by 4 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Transcatheter arterial chemoembolization (TACE) has been previously used for the treatment of liver cancer, and the technology has been widely used in extrahepatic tumors [2]. Drug-eluting embolic microspheres can be loaded with chemotherapy drugs, and therefore they can embolize the tumor blood vessel bed and while releasing drugs.…”

Section: Discussionmentioning

confidence: 99%

Comprehensive Treatment of Mediastinal Neuroendocrine Tumor: A Case Report

Han

2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Comprehensive Treatment of Mediastinal Neuroendocrine Tumor: A Case Report

Han

2021

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…TACE has been previously used for the treatment of liver cancer, and this technology has been widely used in extrahepatic tumors. [ 4 ] Drug-eluting embolic microspheres can be loaded with chemotherapy drugs; therefore, they can embolize the tumor blood vessel bed and release drugs. According to the National Comprehensive Cancer Network guidelines for NETs, etoposide/cisplatin or etoposide/carboplatin are used as first-line drugs.…”

Section: Discussionmentioning

confidence: 99%

“…TACE has been previously used for the treatment of liver cancer, and this technology has been widely used in extrahepatic tumors [4] . Drug-eluting embolic microspheres can be loaded with chemotherapy drugs; therefore, they can embolize the tumor blood vessel bed and release drugs.…”

Section: Discussionmentioning

confidence: 99%

Giant mediastinal neuroendocrine tumor successfully resected after transarterial chemoembolization of drug-eluting embolic microspheres

Qi¹,

Li²,

Han³

2021

Medicine

Self Cite

View full text Add to dashboard Cite

Rationale: Neuroendocrine tumors (NETs) in the mediastinum are extremely rare. No uniform solution currently exists for the treatment of mediastinal NETs. Patient concerns: We report the case of a 32-year-old man with symptoms of chest tightness, chest pain, cough, and panic. Diagnoses: Computed tomography showed that the mediastinum and right lung occupied a space with uneven enhancement. A needle biopsy revealed mediastinal NETs. An atypical carcinoid was diagnosed using immunohistochemistry. Interventions: The patient underwent 2 similar transarterial chemoembolizations of drug-eluting embolic microsphere procedures after 5 cycles of etoposide and cisplatin chemotherapy. The patient underwent successful surgical resection 2 months after the operation. Outcomes: The patient's quality of life was significantly improved, without chest tightness, chest pain, or other symptoms. At the 1-year follow-up, the patient had no tumor recurrence. Lessons: For large mediastinal NETs with poor chemotherapy effects, surgical resection is safe and feasible after down-staging treatment via arterial chemoembolization of drug-eluting embolic microspheres.

show abstract

“…There were relatively few reports on TACE for the treatment of gastric cancer ( 7 ). Some case reports have demonstrated the efficacy and safety of transcatheter arterial therapy in late-stage gastric cancer, indicating that TACE may have more prospects in the treatment of gastric cancer ( 8 , 9 ). TACE can increase the concentration of localized chemotherapy drugs and reduce adverse reactions ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study

Wu,

Li,

et al. 2023

Front. Oncol.

Self Cite

View full text Add to dashboard Cite

PurposeThis study aims to investigate the efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with Apatinib and Camrelizumab for treating unresectable advanced gastric or gastroesophageal junction (G/GEJ) cancer.Material and methodsIn this study, data of patients with unresectable advanced G/GEJ cancer who received TACE combined with Apatinib and Camrelizumab from August 2018 to December 2021 was evaluated. After TACE, patients were given intravenous Camrelizumab 200mg every three weeks and oral apatinib 250mg/day for treatment. The primary endpoint was overall survival (OS), and the secondary endpoints were objective response rate (ORR), disease control rate (DCR), and adverse events (AEs).ResultsA total of 49 patients were enrolled in this study. The median follow-up time was 14.0 months, and the median OS was 20.0 months (95% CI = 13.6-26.4). Two patients (4.08%) achieved complete remission, 28 patients (57.14%) achieved partial remission, 18 patients (36.73%) had stable disease, and 1 patient (2.04%) had disease progression. The ORR was 61.22%, and the DCR was 97.96%. Multivariate Cox regression analysis indicated that age (HR 4.74, 95% CI = 1.674-13.440, P=0.003) and multiple distant metastases (HR 20.916, 95% CI = 4.094-106.808, P = 0.001) were independent risk factors for OS. Most AEs were classified as grade 1-2, the most common being RCCEP (69.39%). There were 5 cases of grade 3-4 adverse events (10.20%). No patients discontinued or reduced the treatment dose due to AEs, and all patients received symptomatic treatment.ConclusionTACE combined with Apatinib and Camrelizumab is a safe and effective therapeutic option for patients with unresectable advanced G/GEJ cancer, which can significantly improve the median OS and ORR of patients. And the adverse events (AEs) are tolerable and manageable.

show abstract

A novel application of drug-eluting transarterial chemoembolization in treating non-liver cancers

Abstract: Supplemental Digital Content is available in the text

Cited by 4 publications

References 25 publications

Comprehensive Treatment of Mediastinal Neuroendocrine Tumor: A Case Report

Comprehensive Treatment of Mediastinal Neuroendocrine Tumor: A Case Report

Giant mediastinal neuroendocrine tumor successfully resected after transarterial chemoembolization of drug-eluting embolic microspheres

Transcatheter arterial chemoembolization combined with apatinib and camrelizumab for unresectable advanced gastric or gastroesophageal junction cancer: a single-arm, single-center, retrospective study

Contact Info

Product

Resources

About